There were 1,576 press releases posted in the last 24 hours and 439,141 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image